From the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham, NC, discusses the recently approved enasidenib and ivosidenib, which target IDH2 and IDH1 mutations in relapsed or refractory patients with acute myeloid leukemia (AML). Dr Erba outlines the outcomes of the CASCADE trial, and suggests that the use of an older, unfit sample and the administration of the highly immunosuppressive vadastuximab talirine with azacitidine may explain the outcome. Despite such challenges that may lead physicians to switch to chemotherapy instead, Dr Erba presents data to convince the healthcare community that gene-targeted treatments for AML are, indeed, most effective.
Gene-targeting therapies for AML
